Beovu (Brolucizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Beovu (Brolucizumab) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to factors such as the rising prevalence of age-related macular degeneration (AMD), increased healthcare expenditure, awareness campaigns for AMD management, government support for innovative treatments, and the growing adoption of precision imaging technologies.

Market growth during the forecast period is expected to be driven by the increasing aging global population, rising demand for targeted biologics, expansion of healthcare infrastructure, favorable reimbursement policies for AMD therapies, and a greater focus on personalized medicine. Key trends in this period include a shift toward biosimilar development, growth in telemedicine for AMD care, the adoption of AI-based diagnostic tools, emphasis on sustainability in drug manufacturing, collaborations between biotech firms and technology companies, and continued product innovation.

The rising prevalence of age-related macular degeneration (AMD) is expected to drive the growth of the beovu (brolucizumab) market in the future. AMD is a progressive eye condition that leads to vision loss in the central field of vision, primarily affecting older adults. This condition is becoming more common due to factors such as increased life expectancy, declining birth rates, and advancements in healthcare. Beovu (brolucizumab) is used to treat AMD by targeting and inhibiting vascular endothelial growth factor (VEGF), which helps improve retinal health and reduce vision loss. For example, a report by the BrightFocus Foundation in March 2023 indicated that approximately 200 million people worldwide are affected by AMD, a number projected to reach 288 million by 2040. Therefore, the increasing prevalence of AMD is expected to drive the expansion of the beovu (brolucizumab) market.

The rise in healthcare expenditure is also expected to contribute to the growth of the beovu (brolucizumab) market. Healthcare expenditure is rising due to factors such as the aging population, the growing prevalence of chronic diseases, and advancements in medical technology that have led to more expensive treatments. The increased spending on healthcare plays a crucial role in managing the costs of treating retinal diseases, particularly AMD, through Beovu's innovative and high-cost treatment regimen. For instance, a report from the Centers for Medicare & Medicaid Services in September 2024 revealed that U.S. healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, or $13,493 per person, which accounted for 17.3% of the nation’s GDP. As a result, the rising healthcare expenditure is expected to drive the growth of the Beovu (brolucizumab) market.

A significant trend in the beovu (brolucizumab) market is the focus on expanding treatment options for retinal diseases through regulatory approvals. Companies are working to secure additional indications, such as diabetic macular edema (DME), to broaden the therapeutic potential of Beovu. Beovu is already used to treat retinal diseases such as wet AMD and DME by inhibiting VEGF-A to reduce abnormal blood vessel growth and prevent vision loss. For example, in March 2022, Novartis AG, a Switzerland-based pharmaceutical company, announced that the European Commission (EC) had approved Beovu (brolucizumab) 6 mg for treating visual impairment caused by DME. This approval marked Beovu’s second indication from the EC, following its initial approval in 2020 for treating wet AMD. The EC's decision applies to all 27 EU member states, as well as Iceland, Norway, and Liechtenstein.

The key company operating in the beovu (brolucizumab) market is Novartis AG.

North America was the largest region in the beovu (brolucizumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in beovu (brolucizumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the beovu (brolucizumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Brolucizumab, marketed under the brand name Beovu, is a monoclonal antibody used to treat retinal diseases, including wet age-related macular degeneration (AMD). It works by inhibiting vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth and fluid leakage in the retina. Beovu provides the advantage of a less frequent dosing schedule compared to other VEGF inhibitors.

The primary indications for beovu (brolucizumab) include neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal disorders. Neovascular AMD is a chronic eye condition marked by abnormal blood vessel growth beneath the retina, leading to fluid leakage, swelling, and potential vision loss. Brolucizumab helps alleviate inflammation and fluid accumulation, leading to improved visual outcomes. It is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is utilized by end users such as specialty clinics and ambulatory care centers.

The beovu (brolucizumab) market research report is one of a series of new reports that provides beovu (brolucizumab) market statistics, including the beovu (brolucizumab) industry's global market size, regional shares, competitors with a beovu (brolucizumab) market share, detailed beovu (brolucizumab) market segments, market trends and opportunities, and any further data you may need to thrive in the beovu (brolucizumab) industry. This beovu (brolucizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The beovu (brolucizumab) market consists of sales of BEOVU vial kits, and Beovu brolucizumab Injection. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.